RESUMEN
Although beta-amyloid (Aß) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer's disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and oxidative stress. In mild cognitive impairment (MCI), a prodromal stage of AD and other neurodegenerative conditions, the joint appearance of inflammation, oxidative stress, and metabolic alterations are the common pathways of neurotoxicity and neurodegeneration. The standardized extract of Ginkgo biloba EGb 761 interferes with the pathogenic mechanisms involved in both the development of cognitive impairment due to AD and that of vascular origin. The primary objective of this study is to compare changes in the levels of blood markers of inflammation and oxidative stress after treatment with EGb 761 in a cohort of 100 patients with MCI. In addition, we aim to assess changes in these blood markers during an additional 12-month extension phase in which patients in the control group will also receive EGb 761 and patients in the active group will extend their treatment duration. Secondary objectives include comparing changes in neuropsychiatric and cognitive test scores between the baseline (v0) and 12-month visits (v2). This study is a Phase IV, single-center, randomized, open-label, parallel-group clinical trial consisting of the 12-month follow-up of a cohort of participants with MCI [Global Deterioration Scale (GDS) = 3] and an extension with an additional 12-month follow-up. During the first 12 months, participants will be randomized into two arms: in one arm, patients will receive 1 daily tablet of EGb 761 240 mg orally (study group, n = 50), while in the other arm, patients will not receive EGb 761 and will undergo the same assessments as the treated group (control group, n = 50). After the first 12 months of the study, patients in the EGb 761-treated group will continue treatment, and patients in the control group will be offered one EGb 761 240 mg tablet per day orally. All participants will be monitored for an additional 12 months. A battery of blood markers of inflammation and oxidative stress will be quantified at v0, v1, v2, v3, and v4. The Olink Proteomics panel of inflammation markers ( https://www.olink.com/products/inflammation/ ) will be used to evaluate 92 proteins associated with inflammatory diseases and related biological processes. The second panel measures 92 proteins involved in neurological processes. At v0, v2, and v4, neuropsychological and neurological evaluations will be conducted in addition to vital signs and anthropometric studies using a body composition monitor with bioimpedance technology (Tanita). Sixty percent of the 100 MCI patients recruited were women. The mean age was 73.1 years, and the mean time between symptom onset and MCI diagnosis was 2.9 years. The mean Mini-Mental State Examination (MMSE) score was 26.7. Depressive and anxiety disorders, as well as vascular risk factors, were the most frequent comorbidities among the cohort. The study is still ongoing, and results for the first year of treatment (v0, v1, v2) are expected by 2023. Individuals with MCI have an elevated risk of developing dementia. EGb 761 is used worldwide for the symptomatic treatment of cognitive disorders due to its neuroprotective effects. In experimental models and clinical observational studies, EGb 761 has shown strong antioxidant and anti-inflammatory activity. As a result, this study has been proposed to evaluate the antioxidant and anti-inflammatory effects on plasma markers and their potential clinical correlation with the progression of cognitive decline in patients with MCI.Trial registration: Registro Español de estudios clínicos (REec) number 2020-003776-41, ClinicalTrials.gov Identifier: NCT05594355.
Asunto(s)
Enfermedad de Alzheimer , Disfunción Cognitiva , Humanos , Femenino , Anciano , Masculino , Antioxidantes/uso terapéutico , Extractos Vegetales/uso terapéutico , Disfunción Cognitiva/complicaciones , Enfermedad de Alzheimer/complicaciones , Inflamación/inducido químicamente , Estrés OxidativoRESUMEN
BACKGROUND: Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. METHODS: This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundació ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. RESULTS: Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). CONCLUSIONS: The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women's health.
Asunto(s)
Enfermedad de Alzheimer , Disfunción Cognitiva , Anciano , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/epidemiología , Ensayos Clínicos como Asunto , Estudios Transversales , Escolaridad , Femenino , Humanos , Masculino , Caracteres SexualesRESUMEN
BACKGROUND: The COVID-19 pandemic has brought great disruption to health systems worldwide. This affected ongoing clinical research, particularly among those most vulnerable to the pandemic, like dementia patients. Fundació ACE is a research center and memory clinic based in Barcelona, Spain, one of the hardest-hit countries. OBJECTIVE: To describe the ad-hoc strategic plan developed to cope with this crisis and to share its outcomes. METHODS: We describe participants' clinical and demographic features. Additionally, we explain our strategic plan aimed at minimizing the impact on clinical trial research activities, which included SARS-CoV-2 RT-PCR and IgG serological tests to all participants and personnel. The outcomes of the plan are described in terms of observed safety events and drop-outs during the study period. RESULTS: A total of 130 patients were participating in 16 active clinical trials in Fundació ACE when the lockdown was established. During the confinement, we performed 1018 calls to the participants, which led to identify adverse events in 26 and COVID-19 symptoms in 6. A total of 83 patients (64%) could restart on-site visits as early as May 11, 2020. All SARS-CoV-2 RT-PCR diagnostic tests performed before on-site visits were negative and only three IgG serological tests were positive. Throughout the study period, we only observed one drop-out, due to an adverse event unrelated to COVID-19. DISCUSSION: The plan implemented by Fundació ACE was able to preserve safety and integrity of ongoing clinical trials. We must use the lessons learned from the pandemic and design crisis-proof protocols for clinical trials.
Asunto(s)
Enfermedad de Alzheimer/terapia , Ensayos Clínicos como Asunto , Infecciones por Coronavirus , Pandemias , Atención al Paciente , Neumonía Viral , Anciano , Instituciones de Atención Ambulatoria , Betacoronavirus , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico , Ensayos Clínicos como Asunto/métodos , Ensayos Clínicos como Asunto/organización & administración , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Femenino , Humanos , Masculino , Pandemias/prevención & control , Atención al Paciente/métodos , Atención al Paciente/tendencias , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , SARS-CoV-2 , España/epidemiología , Telemedicina/métodos , Terapias en Investigación/métodosRESUMEN
Type 2 diabetes is associated with a high risk of cognitive impairment and dementia. Therefore, strategies are needed to identify patients who are at risk for dementia. Given that the retina is a brain-derived tissue, it may provide a noninvasive way to examine brain pathology. The aims of this study were to evaluate whether retinal sensitivity 1) correlates with the specific parameters of brain imaging related to cognitive impairment and 2) discriminates patients with diabetes with mild cognitive impairment (MCI) from those with normal cognition and those with Alzheimer disease (AD). For this purpose, a prospective, nested case-control study was performed and included 35 patients with type 2 diabetes without cognitive impairment, 35 with MCI, and 35 with AD. Retinal sensitivity was assessed by Macular Integrity Assessment microperimetry, and a neuropsychological evaluation was performed. Brain neurodegeneration was assessed by MRI and fludeoxyglucose-18 positron emission tomography (18FDG-PET). A significant correlation was found between retinal sensitivity and the MRI and 18FDG-PET parameters related to brain neurodegeneration. Retinal sensitivity was related to cognitive status (normocognitive > MCI > AD; P < 0.0001). Our results suggest that retinal sensitivity assessed by microperimetry is related to brain neurodegeneration and could be a useful biomarker for identifying patients with type 2 diabetes who are at risk for developing AD.
Asunto(s)
Enfermedad de Alzheimer/etiología , Diabetes Mellitus Tipo 2/complicaciones , Pruebas del Campo Visual , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Femenino , Fluorodesoxiglucosa F18 , Humanos , Imagen por Resonancia Magnética , Masculino , Tomografía de Emisión de Positrones , Estudios ProspectivosRESUMEN
BACKGROUND: Recruitment methods can determine sample characteristics in mild cognitive impairment and Alzheimer's disease dementia, but little is known about its influence in subjective cognitive decline (SCD). OBJECTIVE: To determine the influence of two types of recruitment methods in the characteristics of individuals with SCD. METHODS: We select and compare clinical and neuropsychological features, and frequency of APOE É4 allele of 326 subjects with SCD from two cohorts: Open House Initiative (OHI) versus Memory Unit (MU). A logistic regression analysis (LRA), using gender and years of education as covariates, was used to examine the neuropsychological variables. RESULTS: The OHI sample were mostly women (75.9% versus 64.5%, pâ<â0.05), with higher educational level (12.15 [3.71] versus 10.70 [3.80] years, pâ=â0.001), and more family history of dementia (138 [62.7%] versus 44 [41.5%], pâ<â0.001) than the MU sample. Also, the OHI sample showed better overall neuropsychological performance than the MU sample, and after a LRA, this trend continued in automatic response inhibition capacity, abstract reasoning, and recognition memory. We did not find differences in age, depression history, and/or APOE É4 allele frequency. CONCLUSION: SCD subjects showed different demographic and neuropsychological characteristics depending on the recruitment method, which should be taken into account in the design of research studies with this target population.
Asunto(s)
Disfunción Cognitiva/psicología , Selección de Paciente , Apolipoproteína E4/genética , Disfunción Cognitiva/genética , Autoevaluación Diagnóstica , Escolaridad , Femenino , Predisposición Genética a la Enfermedad , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Factores SexualesRESUMEN
BACKGROUND: The existing pharmacological treatments for Alzheimer's disease (AD) can only slow the progression of symptoms or delay admission to long-term care facilities. The beneficial effects of non-drug treatments are poorly studied. OBJECTIVE: To describe the effects of an Integrated Psychostimulation Program (IPP) in patients with mild-moderate AD treated with acetylcholinesterase inhibitors; and to identify factors related to greater benefit of the IPP. METHODS: 206 patients (mean ageâ=â75.9 years; MMSEâ=â19.6) were evaluated before starting the IPP and 3, 6, 9, and 12 months later. Measures included: Mini-Mental State Examination (MMSE), Cognitive Subscale of Alzheimer's Disease Assessment Scale (ADAS-Cog), Rapid Disability Rating Scale (RDRS-2), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Patients remained cognitively stable (MMSE/ADAS-Cog) for more than 6 months and significantly worsened at 9-month and 12-month follow-ups, without clinically significant functional changes (RDRS-2) or psychiatric symptoms(NPI-Q). The mean annual change on MMSE and ADAS-Cog were 2.06 and 3.56 points, respectively, lower than the annual decline demonstrated previously in similar patients (2.4 and 4.5, respectively). 42.7% of patients maintained or improved global cognitive scores between baseline and 12-month follow-up. The patients who maintained cognitive functions were older than those who did not (77.5 versus 74.7 years). CONCLUSIONS: The IPP may be an effective treatment to maintain cognition, functionality, and psychiatric symptoms in AD patients pharmacologically treated, and older age seems to increase beneficial effects of IPP.
Asunto(s)
Actividades Cotidianas/psicología , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/terapia , Cognición/fisiología , Psicoterapia/métodos , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/psicología , Inhibidores de la Colinesterasa/uso terapéutico , Terapia Combinada , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Introducción. La incidencia del hipotiroidismo congénito es de 1:3.000 a 1:4.000 recién nacidos. El bocio congénito no es una forma de presentación común. Caso clínico. Se presenta el caso de una recién nacida con consanguinidad de primer grado entre los padres, que nace mediante cesárea electiva a las 38 semanas. La somatometría es congruente con la edad gestacional. Es hija de una madre diabética pregestacional con buen control metabólico y función tiroidea previa normal. Se presenta con hipotonía, soplo cardíaco y masa cervical anterior en el tercer día de vida. Se sospecha un hipotiroidismo congénito, diagnóstico que se confirma mediante los datos analíticos (tirotropina elevada con tiroxina indetectable) y la ecografía tiroidea. Se inicia tratamiento sustitutivo con tiroxina de forma inmediata con una notable mejoría clínica y analítica. Comentarios. Se revisan las entidades etiológicas del hipotiroidismo congénito, y se discuten las correlaciones clínicas entre diferentes entidades. Además, se enfatiza la necesidad del tratamiento sustitutivo precoz para asegurar un desarrollo neurocognitivo óptimo(AU)
Introduction. Congenital hypothyroidism occurs in approximately 1:3,000 to 1:4,000 newborns. Congenital goiter is not a common presentation of this disease. Case report. We report the case of a female infant born from first-degree consanguineous parents at 38 weeks of gestational age via elective cesarean section. Somatometry was according to her gestational age. The mother had pre-gestational diabetes mellitus with good metabolic control, and normal thyroid function. The newborn was found to have mild hypotonia, a cardiac murmur, and an anterior cervical mass on the third day of life. Congenital hypothyroidism was suspected; the diagnosis was confirmed by elevated thyrotropin and low free thyroxin, and thyroid sonography. Levothyroxin was started immediately, resulting in a significant clinical improvement. Comments. The causes of congenital hypothyroidism are reviewed, and clinical correlations between the different etiologies are discussed. The need for immediate treatment with levothyroixine to ensure an optimal neurocognitive outcome is emphasized(AU)
Asunto(s)
Humanos , Femenino , Recién Nacido , Hipotiroidismo Congénito/epidemiología , Hipotiroidismo Congénito/prevención & control , Bocio/congénito , Bocio/complicaciones , Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/prevención & control , Hipotiroidismo Congénito/diagnóstico , Hipotiroidismo Congénito/fisiopatología , Edad Gestacional , Diabetes Gestacional/inducido químicamente , Diabetes Gestacional/diagnóstico , Tiroxina/uso terapéuticoRESUMEN
No disponible